This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Microscopic Polyangiitis현미경적 다발동맥염 (현미경적다발동맥염)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: M31.7 | Special Copayment Reduction: V238 (rare disease Special Copayment Reduction)
B. Synonyms—
C. Adult onsetLikelihood of first presentation in adulthood high — the median age at onset is in the 50s–70s, and it is mainly diagnosed in adults. Onset in children is very rare. It is often first diagnosed in adult patients presenting with unexplained rapidly progressive renal failure or pulmonary-renal syndrome.
1. HistoryMicroscopic polyangiitis first described by Davson et al. in 1948 → ANCA discovered by Davies in 1982 → MPA classified independently at the CHCC in 1994 → revised CHCC nomenclature in 2012.
2. CausesMPO-ANCA (p-ANCA) positive in about 60–80%. Environmental triggers (silica and solvent exposure); vascular injury mediated by cooperation of T cells and neutrophils. Absence of granulomas is the key difference from GPA.
3. GeneticsHLA-DQ association (specific to MPO-ANCA MPA); normal α1-antitrypsin alleles. In East Asia, MPO-ANCA-associated MPA predominates over PR3-ANCA-associated GPA.
4. General epidemiologyAbout 2–9 new cases per 100,000 per year; predominance in the 50s–70s; more common than GPA in East Asia (Korea, Japan). Slight male predominance or equal.
5. PathophysiologyMPO-ANCA → full neutrophil activation (degranulation, NETs, oxidative burst) → small-vessel endothelial injury → pauci-immune glomerulonephritis + alveolar hemorrhage. No granulomas.
6. SymptomsSystemic symptoms (fever, weight loss) + kidney (hematuria, proteinuria, rapidly progressive renal failure) + lung (alveolar hemorrhage, hemoptysis) + peripheral neuropathy. No granulomas; nasal and ear involvement rare.
7. SignsMPO-ANCA positive (60–80%); urine: hematuria, red blood cell casts, proteinuria; chest CT: diffuse pulmonary infiltrates; kidney biopsy: pauci-immune crescentic glomerulonephritis. No upper airway involvement or granulomas.
8. ScreeningWith unexplained rapidly progressive renal failure + hematuria + red blood cell casts, immediately order MPO-ANCA + PR3-ANCA and plan a kidney biopsy. When pulmonary-renal syndrome is suspected, add chest CT.
9. DiagnosisMPO-ANCA (ELISA + IIF) + kidney biopsy (pauci-immune crescentic GN) + absence of granulomas + clinical findings of ANCA-associated vasculitis. The 2022 ACR/EULAR criteria are used.
10. TreatmentSame as GPA: remission induction (steroids + rituximab or CYC), remission maintenance (rituximab preferred, or azathioprine). MPO-ANCA-associated MPA relapses less than GPA.
11. Prognosis5-year survival about 65–80%; fewer relapses than GPA (about 20–30%). Risk of progression to end-stage renal failure; infection is the main cause of death. Renal involvement is severe in East Asian MPA.
12. PreventionRituximab maintenance (relapse prevention); TMP-SMX (PCP + adjunct to relapse prevention); early detection of relapse by ANCA follow-up; prevention of osteoporosis and infection.
13. References10 major international journals and guidelines

1. History

The history of microscopic polyangiitis (MPA) is closely linked to the history of the classification of polyarteritis nodosa. The concept of "microscopic polyangiitis" first appeared in 1948, when Davson et al. described a subtype among patients with polyarteritis nodosa in which glomerulonephritis and small-vessel involvement were present. For a long time, however, this subtype was regarded as a variant of polyarteritis nodosa and was not recognized as an independent disease entity.

The decisive turning point came when Davies et al. in Australia discovered ANCA (antineutrophil cytoplasmic antibodies) in 1982, and it was later shown that MPO-ANCA (perinuclear ANCA, p-ANCA) is strongly associated with microscopic polyangiitis and necrotizing glomerulonephritis. The distinction between MPO-ANCA and PR3-ANCA (associated with Wegener granulomatosis) contributed to distinguishing microscopic polyangiitis from Wegener granulomatosis pathogenetically.

At the 1994 Chapel Hill Consensus Conference (CHCC), microscopic polyangiitis was separated from polyarteritis nodosa and formally classified as an independent small-vessel vasculitis. In this classification, microscopic polyangiitis was defined as a necrotizing vasculitis without granulomas that involves small (capillaries, venules, arterioles) and medium-sized vessels, characterized in particular by involvement of pulmonary capillaries (alveolar hemorrhage) and renal glomeruli (pauci-immune glomerulonephritis). In the revised 2012 CHCC nomenclature, microscopic polyangiitis was also retained as a member of the ANCA-associated vasculitis (AAV) group. In Korea it is managed under code M31.7 and Special Copayment Reduction V238.


2. Causes

The pathogenesis of microscopic polyangiitis (MPA) is understood as an MPO-ANCA-centered mechanism among the ANCA-associated vasculitides (AAV), with features that distinguish it from Wegener granulomatosis (PR3-ANCA-centered).

Role of MPO-ANCA: MPO-ANCA (perinuclear fluorescence, p-ANCA pattern) is positive in about 60–80% of patients with MPA. MPO (myeloperoxidase) is an oxidative enzyme stored in the primary granules of neutrophils and is normally used to kill bacteria. When proinflammatory stimuli (TNF-α, IL-8) cause MPO to move to the neutrophil cell surface, circulating MPO-ANCA recognizes it and fully activates the neutrophil via Fcγ receptors. Activated neutrophils damage the vascular endothelium through reactive oxygen species, extracellular release of MPO itself and NETs.

T cell-mediated immunity: an imbalance between CD4+ T cells (Th1, Th17) and regulatory T cells (Treg) contributes to the breakdown of immune tolerance to MPO. Excessive IL-17A secretion further amplifies neutrophil recruitment. Direct injury of vascular endothelial cells by CD4+ T cells has also been reported.

Key difference from GPA: granulomas do not form in MPA. This reflects that the Th2 or mixed immune pattern in MPA differs from the strongly Th1-biased mechanism of PR3-ANCA-associated GPA. In addition, the small-vessel involvement pattern of MPA (arterioles, capillaries, venules) is distinguished from the medium-vessel involvement of polyarteritis nodosa.

Environmental triggers: epidemiologic studies indicate that exposure to silica dust, solvents and pesticides increases the risk of MPO-ANCA-associated vasculitis. Silica exposure in particular is most strongly associated with MPO-ANCA-associated vasculitis.


3. Genetics

The genetics of microscopic polyangiitis (MPA) differ in part from those of other ANCA-associated vasculitides and are distinguished from Wegener granulomatosis (GPA), particularly in HLA associations.

HLA associations: in genome-wide association studies (GWAS), ANCA-associated vasculitides show different HLA associations according to ANCA antibody type (PR3 vs. MPO). In MPO-ANCA-associated MPA, an association with HLA-DQ (particularly HLA-DQB1*05:01) has been reported. In contrast, HLA-DPB1*04:01 is the main susceptibility factor in PR3-ANCA-associated GPA. These results suggest that ANCA antibody type is defined by differences in autoantigen presentation determined by HLA molecules.

SERPINA1 (α1-antitrypsin): whereas the SERPINA1 Z variant (α1-AT deficiency) is a risk factor in PR3-ANCA-associated GPA, this association is absent or much weaker in MPO-ANCA-associated MPA. Because α1-AT is the physiologic inhibitor of PR3 (the autoantigen of GPA), this difference reflects the pathogenetic difference between the two subtypes.

Epidemiologic features in East Asia: in East Asia, including Korea, Japan and China, MPO-ANCA-associated MPA is much more common than PR3-ANCA-associated GPA. In a Japanese vasculitis cohort, the MPA:GPA ratio is reported at about 3–5:1. This reflects a pattern unique to East Asia in genetic background (HLA distribution), environmental factors and epidemiologic characteristics. In Korea, too, MPA is known to be more common than GPA.


4. General epidemiology

Among the ANCA-associated vasculitides (AAV), microscopic polyangiitis (MPA) is the second most common after Wegener granulomatosis in Europe, but it is the most common AAV in East Asia (Korea, Japan, China).

Incidence and prevalence: the annual incidence is reported at about 2–9 per 1 million population, and the prevalence at about 25–94 per 1 million. Regional variation is large.

Sex and age distribution: by sex, men are slightly more numerous or equal. Age at onset is most common in middle-aged to older adults in their 50s–70s, somewhat older than the mean age at onset of GPA (40–65 years). It also occurs rarely in children.

Features in East Asia: in a large epidemiologic study conducted in Japan, the MPA:GPA:EGPA ratio was about 7:1:1, with MPA overwhelmingly predominant. A similar trend is observed in Korea. The MPO-ANCA positivity rate in East Asian MPA is 85–90% or higher, higher than in Western countries (60–80%).

Epidemiology in Korea: the number of patients registered in Korea under M31.7 (microscopic polyangiitis) with Special Copayment Reduction V238 is estimated at several hundred to several thousand. According to Korean rare disease registry data and Health Insurance Review & Assessment Service (HIRA) data, the number of registered patients with MPA is expected to be greater than with GPA.

Epidemiology of renal involvement: renal involvement occurs at diagnosis or during the course in about 70–80% of patients with MPA, a higher proportion than in GPA. The fact that MPO-ANCA-associated renal involvement is more common in East Asia also suggests that the rate of progression to end-stage kidney disease may be higher in this region.


5. Pathophysiology

The core pathophysiology of microscopic polyangiitis (MPA) is small-vessel injury through MPO-ANCA-mediated neutrophil activation; it shares the basic mechanism with Wegener granulomatosis but differs in detail.

MPO-ANCA-mediated neutrophil activation: in normal neutrophils, MPO is stored in primary granules and is not exposed on the cell surface. When proinflammatory cytokines (TNF-α, IL-8) or infection prime the neutrophil, MPO moves to the cell surface. When circulating MPO-ANCA binds surface MPO, the neutrophil is fully activated via Fcγ receptors (FcγRIIa) and MAC-1 (CR3) receptors. Activated neutrophils directly damage vascular endothelial cells through ① generation of large amounts of reactive oxygen species by the oxidative burst, ② extracellular release of MPO and other primary granule contents (elastase, proteinase 3) and ③ formation of NETs (neutrophil extracellular traps).

Vascular endothelial injury and glomerulonephritis: inflammatory cells infiltrate the vessel wall through the damaged endothelium, and when glomerular endothelial cells are destroyed, the basement membrane is exposed. Fibrin deposition and cellular proliferation in Bowman space form crescentic pauci-immune glomerulonephritis (crescentic pauci-immune GN). "Pauci-immune" means that there are almost no immune deposits on immunofluorescence microscopy, distinguishing it from the linear deposits of anti-GBM antibody disease and the granular deposits of immune complex disease.

Mechanism of lung involvement: when the endothelial cells of alveolar capillaries are damaged by MPO-ANCA-mediated neutrophil attack, red blood cells and serum leak into the alveoli, causing diffuse alveolar hemorrhage (DAH). Smoking, infection and fluid overload can be triggers of lung involvement.


6. Symptoms

The clinical presentation of microscopic polyangiitis (MPA) overlaps in many respects with that of Wegener granulomatosis (GPA), but there are several important differences.

Systemic symptoms: fever, weight loss, fatigue, decreased appetite, arthralgia and myalgia appear over weeks to months. As in GPA, systemic inflammatory symptoms are nonspecific and delay diagnosis.

Renal symptoms (the main site of involvement in MPA): renal involvement occurs in about 70–80% of patients, and in the pattern of rapidly progressive glomerulonephritis (RPGN), hematuria (microscopic or gross), red blood cell casts, proteinuria and declining renal function progress rapidly. Without treatment, it progresses to end-stage renal failure within weeks to months. The frequency and severity of renal involvement are reported to be higher than in GPA.

Pulmonary symptoms: lung involvement occurs in about 25–50%, and the most serious manifestation is diffuse alveolar hemorrhage (DAH), with hemoptysis, dyspnea and cough. Alveolar hemorrhage alone is life-threatening, and the pattern of pulmonary-renal syndrome, occurring together with renal involvement, is characteristically observed in MPA.

Clinical differences between MPA and GPA: the upper airway involvement of GPA (epistaxis, nasal septal perforation, saddle nose, sinusitis) and granulomatous lesions do not occur in MPA. Pulmonary nodules and cavities are rarer in MPA than in GPA. In contrast, the combination of renal involvement and alveolar hemorrhage is more typical of MPA.

Other symptoms: peripheral neuropathy (mononeuritis multiplex), skin (purpura, ulcers, livedo reticularis), arthritis, pericarditis and gastrointestinal involvement may occur.


7. Signs

Physical signs and test findings of microscopic polyangiitis (MPA) are evaluated with a focus on renal and pulmonary involvement.

Laboratory findings: MPO-ANCA (p-ANCA) positive — about 60–80% (confirmed by combined ELISA and IIF); markedly elevated ESR and CRP; complete blood count (leukocytosis, anemia, thrombocytosis); elevated serum creatinine (degree of renal failure); elevated BUN; urinalysis — hematuria, red blood cell casts (marker of glomerulonephritis), proteinuria. ANCA-negative MPA (about 20–40%) can also be diagnosed by clinical findings + biopsy.

Pulmonary findings: bilateral diffuse alveolar infiltrates (alveolar hemorrhage) and ground-glass opacities on chest X-ray and CT. Unlike GPA, pulmonary nodules and cavities are rare. Bronchoalveolar lavage (BAL) shows bloody lavage fluid and hemosiderin-laden macrophages.

Kidney biopsy findings: the key test for pathologic confirmation of MPA. Light microscopy shows crescentic glomerulonephritis (crescent formation in 50% or more of glomeruli). Immunofluorescence microscopy shows no or very few immune deposits (pauci-immune) — a finding common to GPA and MPA, distinguishing them from the linear deposits of Goodpasture syndrome and the granular deposits of lupus. Electron microscopy shows no immune electron-dense deposits.

Absence of granulomas: the absence of granulomas on tissue biopsy is the pathologic key that distinguishes MPA from GPA. For the diagnosis of MPA to be maintained, there must be no granulomas on biopsy from any site, including nasal and lung biopsies.


8. Screening

There is no population-wide screening test for microscopic polyangiitis (MPA). Immediate screening evaluation is essential when rapidly progressive renal failure (RPGN) or pulmonary-renal syndrome appears.

Indications for immediate evaluation: evaluation for ANCA-associated vasculitis, including MPA, is performed immediately in the following situations. Renal decline progressing rapidly over days to weeks (sharp rise in serum creatinine); unexplained hematuria + red blood cell casts + proteinuria; alveolar hemorrhage (hemoptysis, dyspnea) + renal decline (pulmonary-renal syndrome); a combination of unexplained markedly elevated ESR and CRP + weight loss + renal decline.

Screening tests to perform immediately: MPO-ANCA (ELISA and IIF), PR3-ANCA (for differentiation); urinalysis (urine sediment: red blood cell casts, microscopic hematuria, quantitative proteinuria); serum creatinine, BUN; anti-GBM antibody ELISA (to differentiate Goodpasture syndrome); ANA, anti-double-stranded DNA antibody (to differentiate lupus); complement (C3, C4); chest X-ray or CT (to confirm alveolar hemorrhage).

Importance of rapid diagnosis: in RPGN due to MPA, the level of renal function at the start of treatment determines whether renal function recovers. Because the risk of irreversible loss of renal function increases the longer treatment is delayed, it is recommended to start treatment immediately, without waiting for kidney biopsy results, once ANCA positivity + RPGN findings are confirmed.


9. Diagnosis

The diagnosis of microscopic polyangiitis (MPA) is established by integrating clinical findings, ANCA testing and kidney biopsy.

ANCA testing: MPO-ANCA (p-ANCA) positivity is the key test finding for the diagnosis of MPA. Combined use of ELISA and indirect immunofluorescence (IIF) is recommended, and ELISA alone has higher specificity than IIF. If PR3-ANCA is positive, the possibility of GPA is considered first, but PR3-ANCA positivity is possible in a minority of MPA as well. Even when ANCA is negative, MPA can be diagnosed by clinical findings and biopsy.

Kidney biopsy: the most important test for confirming MPA. Confirmation of pauci-immune crescentic glomerulonephritis without granulomas is consistent with MPA. Biopsy is performed before treatment or immediately upon starting treatment and is used for diagnosis and prediction of prognosis (proportion of crescents).

2022 ACR/EULAR classification criteria: in 2022, ACR/EULAR published revised MPA classification criteria. These criteria are used complementarily with the GPA criteria and score absence of upper airway involvement, absence of pulmonary cavities and nodules, ANCA type (MPO vs. PR3), renal involvement, alveolar hemorrhage, biopsy findings and others. The 2022 criteria have improved sensitivity and specificity compared with previous classifications based on the 2012 CHCC definitions.

Differential diagnosis: differentiation is needed from GPA (presence of granulomas, PR3-ANCA), Goodpasture syndrome (anti-GBM antibodies, linear IgG deposits), lupus nephritis (ANA, anti-dsDNA, granular deposits), cryoglobulinemic vasculitis (cryoglobulins, HCV), STEC-HUS and others.


10. Treatment

Treatment of microscopic polyangiitis (MPA) follows the same principles of ANCA-associated vasculitis treatment as Wegener granulomatosis (GPA). The 2022 ACR/EULAR guidelines present the latest standard.

Remission induction therapy: when there is major organ involvement such as renal involvement or alveolar hemorrhage, combination of high-dose glucocorticoids and an immunosuppressant is standard. Intravenous methylprednisolone pulse therapy (500–1,000 mg × 3 days) followed by oral prednisolone (1 mg/kg/day) + rituximab or cyclophosphamide (CYC). In the RAVE trial, rituximab showed remission induction efficacy equivalent to CYC and was also favorable in terms of toxicity, so it is currently recommended as the first choice. CYC is considered preferentially when rituximab cannot be used or in extremely severe disease (simultaneous alveolar hemorrhage + renal failure).

Plasma exchange: plasma exchange combined with immunosuppression was traditionally used when life-threatening alveolar hemorrhage or acute renal failure at a dialysis-dependent level was present, but the PEXIVAS trial (2020) found that plasma exchange did not reduce end-stage kidney disease or death, so routine use is currently not recommended. However, its use may be considered on an individual basis in patients with severe alveolar hemorrhage.

Remission maintenance therapy: rituximab (500 mg every 6 months, for 2 years or longer) is currently the first-line recommended maintenance therapy. Azathioprine (2 mg/kg/day) or mycophenolate mofetil (MMF, 2 g/day) can also be used as alternatives. Because MPO-ANCA-associated MPA has a lower relapse rate than PR3-ANCA-associated GPA, shortening the duration of treatment may be considered in some patients.

Dialysis and kidney transplantation: when the disease has progressed to end-stage renal failure, hemodialysis or peritoneal dialysis is required. Kidney transplantation is considered after ANCA antibodies become negative and a certain period (usually 1–2 years) has passed, and maintenance immunosuppression is continued after transplantation to prevent recurrence.

Prevention of immunosuppression complications: TMP-SMX (PCP prophylaxis), osteoporosis prevention (calcium, vitamin D, bisphosphonates), vaccination (influenza, pneumococcal), monitoring of blood glucose and weight.


11. Prognosis

The prognosis of microscopic polyangiitis (MPA) was very poor before treatment was available, but it has improved considerably with modern immunosuppressive therapy. Five-year survival is reported at about 65–80%.

Main prognostic factors: renal function at diagnosis (serum creatinine), proportion of crescents on kidney biopsy, presence of alveolar hemorrhage and age are important prognostic factors. If creatinine at diagnosis is >5.7 mg/dL (500 μmol/L) or at a dialysis-dependent level, the likelihood of renal recovery is markedly reduced. Mortality is high in older patients.

Relapse: the relapse rate of MPA is lower than that of GPA, reported at about 20–30%. MPO-ANCA-associated MPA in particular relapses less than PR3-ANCA-associated GPA. However, because renal damage accumulates with relapse, follow-up is needed.

Causes of death: infection due to immunosuppressive therapy (pneumonia, sepsis, PCP) is the most common cause of death. Active vasculitis (alveolar hemorrhage, renal failure) is also an important cause of early death. The risk of immunosuppression-related malignancies (bladder cancer, skin cancer, lymphoma) also contributes to long-term morbidity.

Features of MPA in East Asia: patients with MPA in East Asia (Korea, Japan) have been reported to have more severe renal involvement than in Western countries and to tend to have more severe renal impairment at diagnosis. This suggests that diagnostic delay may be more common in East Asian MPA or that the biological progression of renal involvement may be faster.

Long-term complications: chronic renal failure, end-stage kidney disease, dialysis dependence, hearing impairment (rarely), sequelae of peripheral neuropathy and complications of long-term steroid and CYC administration contribute to long-term morbidity.


12. Prevention

There is no primary prevention for microscopic polyangiitis (MPA). Prevention of relapse, minimization of treatment complications and preservation of renal function are the key goals of clinical management.

Relapse prevention: rituximab maintenance therapy after achieving remission (500 mg every 6 months) is the first-line strategy for relapse prevention. In the MAINRITSAN study series, rituximab significantly reduced the relapse rate compared with azathioprine. Relapse risk is monitored by regular measurement of MPO-ANCA titers (a rise in titer sometimes precedes relapse, but changing treatment based on ANCA titer alone is not recommended). A gradual and careful approach is needed when tapering steroids.

TMP-SMX (trimethoprim-sulfamethoxazole): TMP-SMX prophylaxis to prevent PCP (Pneumocystis jirovecii pneumonia) during immunosuppressive therapy is standard care. Unlike in GPA, the relapse-preventing effect of TMP-SMX in MPA is limited, but it may help when there is nasal colonization with Staphylococcus aureus.

Prevention of immunosuppression complications: osteoporosis prevention (calcium 1,000–1,500 mg/day, vitamin D 800–1,000 IU/day, bisphosphonates); inactivated influenza and pneumococcal vaccination; prevention of bladder toxicity when cyclophosphamide is used (mesna, adequate fluid intake); consideration of IVIG replacement if hypogammaglobulinemia develops during rituximab treatment.

Renal protection: aggressive control of hypertension (target blood pressure below 130/80 mmHg), avoidance of nephrotoxic drugs (NSAIDs, contrast agents) and adequate fluid intake are important for preventing chronic renal decline.

Patient education: patients are educated to recognize symptoms of relapse (recurrent hematuria, hemoptysis, rapid renal decline, recurrent fever and weight loss) and to contact rheumatology immediately. Regular urinalysis (hematuria, proteinuria) and self-measurement and recording of blood pressure are taught.


13. References

  1. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1-11. DOI: 10.1002/art.37715.

  2. Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis (RAVE trial). N Engl J Med. 2010;363(3):221-232. DOI: 10.1056/NEJMoa0909905.

  3. Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis (MAINRITSAN). N Engl J Med. 2014;371(19):1771-1780. DOI: 10.1056/NEJMoa1404231.

  4. Walsh M, Merkel PA, Peh CA, et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis (PEXIVAS). N Engl J Med. 2020;382(7):622-631. DOI: 10.1056/NEJMoa1803537.

  5. Watts RA, Lane SE, Bentham G, Scott DG. Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. Arthritis Rheum. 2000;43(2):414-419. PMID: 10693881.

  6. Lyons PA, Rayner TF, Trivedi S, et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med. 2012;367(3):214-223. DOI: 10.1056/NEJMoa1108735.

  7. Pagnoux C, Guilpain P, Guillevin L. Churg-Strauss syndrome. Curr Opin Rheumatol. 2007;19(1):25-32. PMID: 17143096.

  8. Mahr A, Guillevin L, Poissonnet M, Aymé S. Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis, and Churg-Strauss syndrome. Arthritis Rheum. 2004;51(1):92-99. PMID: 14872461.

  9. Furuta S, Jayne DR. Antineutrophil cytoplasm antibody-associated vasculitis: recent developments. Kidney Int. 2013;84(2):244-249. DOI: 10.1038/ki.2013.100.

  10. Fujimoto S, Watts RA, Kobayashi S, et al. Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the U.K. Rheumatology (Oxford). 2011;50(10):1916-1920. DOI: 10.1093/rheumatology/ker205.